Andrew Ciupek, PhD
Professional Title: Associate Director, Clinical Research, GO2 for Lung Cancer, Washington, DC
Bio: Andrew Ciupek, PhD, is Associate Director of Clinical Research at GO2 for Lung Cancer. Originally a translational cancer researcher, Andrew transitioned to patient-advocacy to have increased impact on driving patient-centered research.
At GO2, Andrew leads implementation of patient-centric research both with external collaborators and within the organization’s Centers of Excellence (COE), a network of community and academic clinical centers focused on lung cancer early detection and treatment. He also serves as a navigator for the organization’s treatment and clinical trial navigation program, called LungMATCH, directly working with lung cancer patients and their caregivers to help them understand and access appropriate care options, empowering them to take an informed, active role in medical decisions.
As a research scientist Andrew studied mechanisms of resistance to cancer therapies as well as novel therapeutic targets. He has worked at several institutions, including Baylor College of Medicine, Medical University of South Carolina, and the University of Maryland’s Greenebaum Cancer Center.
Andrew received a PhD in Translational Biology and Molecular Medicine from Baylor College of Medicine and a BS in Biochemistry from the University of Maryland Baltimore County.
Financial relationships
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:NovartisDate added:06/28/2024Date updated:06/28/2024
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:SeagenDate added:06/28/2024Date updated:06/28/2024
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:GileadDate added:06/28/2024Date updated:06/28/2024
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:RegeneronDate added:06/28/2024Date updated:06/28/2024
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:Daiichi SankyoDate added:06/28/2024Date updated:06/28/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:Glaxo Smith KlineTopic:Honoraria for advisory panel attendanceDate added:06/28/2024Date updated:06/28/2024
-
Attribution:SelfType of financial relationship:TravelIneligible company:Glaxo Smith KlineTopic:Travel to advisory board meetingDate added:06/28/2024Date updated:06/28/2024